(4)The International Diabetes Federation, Prevalence / All diabetes. Disponible en http://www.eatlas.idf.org/Prevalence/All_diabetes/.
(5)Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999; 281 (21):2005-2012.
(6)The International Diabetes Federation, Prevalence / All diabetes. Disponible en http://www.eatlas.idf.org/Prevalence/All_diabetes/.
(7)The International Diabetes Federation, Complications. Disponible en http://www.eatlas.idf.org/Complications/
(8)The International Diabetes Federation, Diabetes Atlas, Second edition. The Economic Impact of Diabetes. 2003: 186.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
(Logo: http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO )
Derin Denham de Lilly, +1-317-277-6749, móvil, +1-317-370-1435; o Alice Bahner Izzo de Amylin, +1-858-642-7272, móvil, +1-858-232-9072 ; Foto: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO , http://www.newscom.com/cgi-bin/prnh/20060610/AMYLINLOGO, PRN Photo Desk, photodesk@prnewswire.com
